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Regulation of NF-κB by PML and 
PML-RARα
Abrar Ahmed1, Xiaochun Wan2, Izaskun Mitxitorena3, Andrew J. Lindsay1, Pier Paolo 
Pandolfi4, Mary W. McCaffrey1, Karen Keeshan5, Youhai H. Chen6 & Ruaidhrí J. Carmody7
Promyelocytic Leukemia (PML) is a nuclear protein that forms sub-nuclear structures termed nuclear 
bodies associated with transcriptionally active genomic regions. PML is a tumour suppressor and 
regulator of cell differentiation. We demonstrate that PML promotes TNFα-induced transcriptional 
responses by promoting NF-κB activity. TNFα-treated PML−/− cells show normal IκBα degradation 
and NF-κB nuclear translocation but significantly reduced NF-κB DNA binding and phosphorylation 
of NF-κB p65. We also demonstrate that the PML retinoic acid receptor-α (PML-RARα) oncofusion 
protein, which causes acute promyelocytic leukemia, inhibits TNFα induced gene expression and 
phosphorylation of NF-κB. This study establishes PML as an important regulator of NF-κB and 
demonstrates that PML-RARα dysregulates NF-κB.
The promyelocytic leukaemia (PML) gene was originally identified at the t(15:17) translocation breakpoint 
characteristic of acute promyelocytic leukaemia (APL) which leads to the formation of a PML-retinoic acid 
receptor-alpha (RARα ) fusion protein (PML-RARα )1. PML is indispensable for the formation of PML nuclear 
bodies; sub-nuclear proteinaceous structures 0.2 to 1μ m in size2 that are attached to the nuclear matrix and asso-
ciated with chromosomal regions of high transcriptional activity3,4. PML nuclear bodies form stable and transient 
interactions with a large number of proteins and play an important regulatory role in apoptosis, cell cycle and 
transcription, which appears dependent on interacting partners3. PML nuclear bodies have been proposed to 
serve as sites of protein modification by facilitating the co-localisation of modifier proteins such as kinases, acetyl 
transferases, phosphatases, ubiquitin and SUMO E3 ligases, and deubiquitinases, and their substrates5.
Studies using PML−/− mice have revealed PML as a tumour suppressor and regulator of retinoic acid-induced 
myeloid differentiation6. In addition, PML−/− mice show defective innate immunity in response to Listeria mono-
cytogenes infection, and develop spontaneous granulomas due to impaired macrophage function7. The molecular 
basis for the regulation of innate immunity by PML however, has not been fully elucidated, although previous 
studies may indicate a role for the NF-κ B transcription factor8,9. NF-κ B is a key regulator of the immune response 
and also regulates gene expression influencing cell survival, proliferation and differentiation10. PML is required 
for TNFα and DNA damage induced activation of IKKε which in turn phosphorylates NF-κ B p65 at S468 to 
modulate the expression of a subset of NF-κ B target genes8,9. However, whether this is sufficient to explain the 
role of PML in innate immunity is currently not clear.
The PML-RARα fusion is a major causative factor for the development of APL1. PML-RARα blocks the dif-
ferentiation of promyelocytes which leads to the proliferation of leukaemia blasts1. PML-RARα delocalises PML 
from nuclear bodies resulting in disrupted nuclear body structure and function11. The PML-RARα enforced 
differentiation block in promyelocytes is reversed by treatment with all-trans retinoic acid (ATRA) or As2O3, 
both of which trigger the degradation of PML-RARα protein and lead to the restoration of PML nuclear bodies12.
In this study, we investigate TNFα -induced transcriptional responses in PML−/− cells. Our data reveals a 
critical role for PML in promoting TNFα responses, in particular the transcription of NF-κ B target genes. Our 
analyses demonstrate reduced TNFα -induced NF-κ B transcriptional activity and DNA binding in the absence 
1Department of Biochemistry, University College Cork, Cork, Ireland. 2Shenzhen Institutes of Advanced Technology, 
Shenzhen, China. 3GLAZgo Discovery Centre, Institute of Infection, Immunity & Inflammation, College of Medicine, 
Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. 4Department of Pathology, Beth 
Israel Deaconess Medical Centre, Harvard University, Boston, MA, 02215, USA. 5Paul O’Gorman Leukaemia Research 
Centre, College of Medicine, Veterinary and Life Sciences, Institute of Cancer Sciences, University of Glasgow, United 
Kingdom. 6Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 19104, 
USA. 7Centre for Immunobiology, Institute of Infection, Immunity & Inflammation, College of Medicine, Veterinary 
and Life Sciences, University of Glasgow, Glasgow, United Kingdom. Correspondence and requests for materials 
should be addressed to R.J.C. (email: ruaidhri.carmody@glasgow.ac.uk)
Received: 13 September 2016
Accepted: 10 February 2017
Published: 20 March 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:44539 | DOI: 10.1038/srep44539
of PML. PML−/− cells also showed significantly reduced phosphorylation of p65 at a number of sites following 
TNFα treatment, establishing PML as a broad regulator of NF-κ B phosphorylation. Moreover, our data shows 
that the oncofusion PML-RARα inhibits TNFα -induced expression of NF-κ B target genes and also blocks p65 
phosphorylation. A bioinformatic analysis of APL transcriptomic datasets provides additional evidence for the 
suppression of NF-κ B target genes by PML-RARα .
Results
PML promotes TNFα-induced gene expression. To investigate the role of PML in TNFα -induced 
responses we performed a microarray analysis of TNF-α treated wild type (WT) and PML−/− mouse embryonic 
fibroblasts (MEFs). Analysis revealed three distinct clusters of TNF-α -inducible genes which were reduced in 
PML−/− cells compared to WT cells (Fig. 1A). The genes in these clusters represent more than 50% of all genes 
induced by 2 fold or greater following TNFα treatment. Analysis of the promoter sequences of genes within 
these clusters revealed a significant over representation of NF-κ B binding sites (Fig. 1A). The PML-dependent 
expression of selected TNFα -inducible genes (IL-6, NFKBIA, ICAM1 and CXCL2) was confirmed by QPCR in 
independent samples (Fig. 1B) and in WT cells transfected with PML siRNA (Fig. 1C and D). Together these 
data demonstrate that PML promotes TNFα -induced transcriptional responses and that NF-κ B target genes are 
selectively regulated by PML.
Defective NF-κB transcriptional activity in PML−/− cells. We next assessed p65 NF-κ B transcrip-
tional activity in WT and PML−/− cells transfected with NF-κ B luciferase reporter. PML−/− cells demonstrated 
significantly lower NF-κ B reporter activity relative to WT cells upon co-transfection with a p65 expression plas-
mid (Fig. 2A). Co-transfection of PML restored NF-κ B reporter activity in PML−/− cells to levels comparable 
WT controls (Fig. 2A). In addition, co-transfection of HEK293T cells with PML and p65 significantly enhanced 
NF-κ B reporter activity compared to cells transfected with p65 (Fig. 2B). EMSA analysis demonstrated reduced 
TNFα -inducible NF-κ B DNA binding in PML−/− cells compared to WT controls (Fig. 2C). Supershift EMSA 
analysis using anti-p65 showed that PML−/− cells have reduced p65 DNA binding following TNFα treatment. 
Furthermore, incubation of EMSA reactions with anti-PML antibodies did not lead to a detectable supershift 
strongly suggesting that that PML itself is not associated with NF-κ B DNA complexes (Fig. 2D). Transfection of 
PML restored TNFα -induced NF-κ B DNA binding in PML−/− cells (Fig. 2E) and enhanced NF-κ B DNA binding 
when co-transfected with p65 (Fig. 2F). TNFα treated WT and PML−/− cells demonstrated equivalent phospho-
rylation and degradation of Iκ Bα (Fig. 3A), and nuclear translocation of NF-κ B p65 (Fig. 3B). Together these data 
demonstrate that PML regulates NF-κ B independently of Iκ Bα degradation and nuclear translocation.
PML regulates NF-κB p65 phosphorylation. Previous studies identified a role for PML in the activa-
tion of IKKε which phosphorylates p65 at S468 to inhibit the expression of genes including Icam1 and Csf28,9. 
However, our data shows that PML promotes the TNFα -induced expression of both Icam1 and Csf2 (Fig. 1A) 
demonstrating that the regulation of NF-κ B activity by PML is distinct from its role in regulating IKKε activa-
tion. Thus our data identifies a critical role for PML in promoting NF-κ B activity which is not explained by IKKε 
mediated phosphorylation of p65. Indeed, our analysis demonstrates reduced phosphorylation of p65 at S536 in 
addition to S468 following TNFα treated PML−/− cells (Fig. 4A), as well as reduced IL1β -induced phosphoryl-
ation of p65 at S276, S468 and S536 (Fig. 4B). We did not detect TNFα -induced phosphorylation of p65 at S276 
(supplementary Figure S1). This establishes PML as a broad regulator of cytokine-induced p65 phosphorylation.
PML-RARα inhibits TNFα responses. The PML-RARα oncofusion leads to the development of APL and 
dysregulated normal PML function1. We tested the effect of PML-RARα expression on TNFα -induced expression 
of NF-κ B genes target genes. PML-RARα transfection in WT MEFs inhibited TNF-induced expression of IL-6, 
Icam1, Cxcl2 and Wnt11. Moreover, PML-RARα expression also inhibited TNFα induced phosphorylation of 
p65 at S468 and S536 (Fig. 5B). Thus, PML-RARα expression recapitulates the PML−/− phenotype with respect 
to NF-κ B and establishes PML-RARα as an inhibitor of NF-κ B. Treatment of cells with ATRA or As2O3 induces 
PML-RARα degradation and differentiation of APL cells12. Treatment of the PML-RARα expressing APL cell 
line NB4 with As2O3 dose dependently increased the expression of Icam1 and Wnt11 expression (Fig. 6A) and 
significantly increased TNFα -induced expression compared to controls (Fig. 6B). As2O3 treatment also increased 
TNFα -induced phosphorylation of p65 at S276, S468 and S536 (Fig. 6C). Analysis of available transcriptomic 
datasets13 revealed an enrichment of NF-κ B binding sites in genes upregulated by ATRA treatment of NB4 cells 
and in genes bound by PML-RARα (Table 1). Gene ontology analysis of the genes bound by PML-RARα and 
containing NF-κ B binding sites revealed an enrichment of genes involved in haematopoiesis, immune system 
development and myeloid cell differentiation, suggesting that PML-RARα blockade of NF-κ B activity may also 
contribute to the block in myeloid cell differentiation seen in APL (Table 2).
Discussion
Here we have identified PML as a key regulator of TNFα -induced transcriptional responses through the NF-κ B 
transcription factor. This important role for PML in regulating NF-κ B transcriptional activity may also contribute 
to the observed immunodeficiences of PML−/− mice7 and the phenotype of APL. Indeed, our analysis of mac-
rophages from WT and PML−/− mice shows a significant reduction of NF-κ B DNA binding and reduced expres-
sion of the NF-κ B target genes IL-12p40 and TNFα in LPS stimulated PML−/− macrophages compared to WT 
controls (Supplementary Figure S2). In addition, we show that expression of the PML-RARα oncofusion protein 
recapitulates the PML−/− phenotype and establishes PML-RARα as a negative regulator of NF-κ B.
PML nuclear bodies are associated with regions of active transcription14,15 and are localised within the nucleus 
in a locus specific manner14,16–19. PML interacts with a number of proteins in the nucleus which perform a wide 
range of cellular functions including regulation of the cell cycle, apoptosis and DNA damage repair20. Our data 
www.nature.com/scientificreports/
3Scientific RepoRts | 7:44539 | DOI: 10.1038/srep44539
further defines a role for PML in promoting NF-κ B transcriptional activity and shows that PML acts as a broad 
regulator of NF-κ B phosphorylation. A role for PML in the activation of IKKε has previously been described. 
Among other substrates, IKKε may also phosphorylate NF-κ B p65 at S468 to both increase and decrease the 
expression of a number of NF-κ B target genes8,9. Our data, however, suggests that PML plays a much broader role 
in regulating NF-κ B activity by promoting the TNFα - and IL1β -inducible phosphorylation of a number of sites 
of p65 including S536 and S276 which is not dependent on IKKε activity8,9,21. Moreover, our analysis shows that 
PML promotes the expression of genes that are inhibited by IKKε phosphorylation of p65 at S468, demonstrating 
Figure 1. PML promotes TNFα-induced expression of NF-κB target genes. (A) Microarray mRNA 
expression data from wild type (WT) and PML−/− MEFs untreated (− ) or treated (+ ) with TNFα (10 ng/ml) 
for 3 hours were analysed by K-means clustering. Red represents TNFα -stimulated gene induction and green 
represents repression. Data is normalised on a per row basis relative to untreated WT cells. Clusters 1, 2 and 3 
indicate genes expressed at reduced in PML−/− cells relative to wild type (WT). The average fold induction of 
each cluster in WT (orange) and PML−/− (blue) cells following TNFα treatment is presented. For each cluster 
the most significantly enriched transcription factor binding site within − 2 to + 2 kb of the transcriptional start 
sites were identified. Shown is the sequence logo for the RELA, NFKB1 and NF-kappaB matrix models in the 
JASPAR CORE database of transcription factor binding sites. (B) WT and PML−/− MEFs were stimulated with 
TNFα (10 ng/ml) for the indicated time points and IL-6, NFKBIA, CXCL2 and ICAM1 mRNA levels assessed 
by QPCR. mRNA levels are expressed relative to unstimulated WT MEFs. (C) WT MEFs were transfected with 
control and PML specific siRNA prior to stimulation with TNFα (10 ng/ml) for the indicated time points. IL-6, 
NFKBIA, CXCL2 and ICAM1 mRNA levels were assessed by QPCR and expressed relative to unstimulated 
control siRNA transfected WT MEFs. (D) Immunoblot analysis of WT MEF cells transfected with control or 
PML siRNA using anti-PML and anti-β -actin antibodies. Data presented are mean ± SEM of triplicate cultures 
and representative of three independent experiments. Statistical significance determined by two-way ANOVA; 
p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).
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that the role of PML in regulating NF-κ B is distinct from the regulation of IKKε activation. In contrast to the find-
ings presented here a previous study suggested that PML negatively regulates NF-κ B activity to promote apop-
tosis22. The reasons for the different findings between that study and this are unclear but our study is supported 
by data from PML−/− MEFs and macrophages as well as our analysis of PML-RARα expression which exerts a 
dominant negative effect on PML.
PML nuclear bodies are sites of dynamic protein-protein interactions and have been proposed to serve as sites 
of protein modification in the nucleus3. Our data suggests that PML promotes the phosphorylation of NF-κ B 
Figure 2. PML regulates NF-κB. (A) Luciferase assay using a NF-κ B consensus reporter plasmid in WT or 
PML−/− MEF cells co-transfected with an expression vector for p65 or increasing amounts of PML expression 
vector as indicated. Data presented are mean ± SEM of triplicate cultures and representative of three 
independent experiments. (B) Luciferase assay using NF-κ B consensus reporter plasmid in HEK293T cells 
transfected with expression vectors for p65 and PML as indicated. Data presented are mean ± SEM of triplicate 
cultures and representative of three independent experiments. (C) WT and PML−/− MEFs were stimulated with 
TNFα (10 ng/ml) for the indicated times analysed by EMSA using oligonucleotides for the consensus NF-κ 
B binding site. (D) WT and PML−/− MEFs were stimulated with TNFα (10 ng/ml) for one hour and analysed 
by EMSA using oligonucleotides for the consensus NF-κ B binding site and antibodies against p65 and PML as 
indicated. (E) PML−/− MEFs were transfected with empty vector or an expression vector for human PML and 
left untreated or treated with TNFα (10 ng/ml) for one hour as indicated. Untransfected WT cells treated with 
TNFα (10 ng/ml for one hour) or left untreated were used as controls. Nuclear lysates used in the EMSA (input) 
were analysed by immunoblot using the indicated antibodies. For the detection of PML a mouse specific anti-
PML antibody was used. (F) PML−/− cells were transiently transfected with PML-FLAG and p65 and analysed 
by EMSA using oligonucleotides for the consensus NF-κ B binding site. Nuclear lysates used as input for EMSA 
were analysed by immunoblot using the antibodies indicated. Immunoblot for HDAC1 was used as a loading 
control. Data presented is representative of at least three independent experiments. Statistical significance 
determined by t test, p < 0.05 (*).
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on at least three sites. A number of kinases of NF-κ B, such as PKA, IKKε , CK2, and ATM, as well as the NF-κ B 
phosphatase PP2a, have been demonstrated to interact with PML nuclear bodies5 suggesting one possible mech-
anism by which PML may promote NF-κ B transcriptional activity. However, it is also possible that PML plays an 
indirect role in regulating NF-κ B activity through other regulatory factors.
We have also demonstrated that PML-RARα expression blocks the transcription of TNF-α -induced 
NF-κ B target genes and p65 phosphorylation similar to PML deficiency. These findings identify PML-RARα 
as a negative regulator of NF-κ B activity. Our analysis of the data from the study of Martens et al.13 identified 
an over-representation of NF-κ B binding sites in genes repressed by PML-RARα , many of which play a role in 
regulating myeloid cell differentiation. Previous studies have demonstrated that the inhibition of NF-κ B does not 
block ATRA induced granulocytic differentiation of APL cells but does significantly increase ATRA-induced cell 
Figure 3. Normal NF-κB activation in PML−/− cells. (A) WT and PML−/− MEFs were stimulated with TNFα 
(10 ng/ml) for the indicated times and analysed by immuno-blotting with the indicated antibodies. (B) Nuclear 
translocation of p65 in TNFα treated WT and PML−/− MEFs was assessed by confocal microscopy.
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death23. Taken together with our data, this suggests that while the suppression of NF-κ B activity by PML-RARα 
may potentially contribute to the differentiation block characteristic of APL, NF-κ B activation is not essential to 
ATRA-induced granulocytic differentiation of APL cells.
Methods
Cell Culture, Transfection, and siRNA Knockdown. Wild type and PML−/− mouse embryonic fibro-
blasts (MEF) and HEK293T cells were maintained in Dulbecco’s modified eagle medium (DMEM) containing 
10% v/v foetal bovine serum, 2 mM glutamine and 100 U/ml penicillin/streptomycin at 37 °C and 5% CO2. 
Plasmids used were pRK5 FLAG-PMLIV (human), pCMV FLAG p65 (mouse), pGL3B NF-κ B consensus lucif-
erase reporter plasmid and pRL-TK renilla luciferase plasmid as previously described24. Transfection of expres-
sion plasmids was carried out using Turbofect (Fermentas) for HEK293T cells and Attractene (Qiagen) for MEF 
cells. Control or PML siRNA (5′ -CCCAGCATATCTACTCCTTTA-3′ ) was transfected with Hiperfect (Qiagen).
Gene expression analysis. RNA was extracted by RNeasy kit (Qiagen). Realtime PCR (qPCR) was per-
formed using primer sequences as previously described25 and relative mRNA levels were calculated using the 
Δ Δ CT method. Microarray analysis was performed by Beckmann Genomics and analysed using ArrayStar 
(DNAStar). Data are available at the NCBI Gene Expression Omnibus (GSE47828). NF-κ B luciferase reporter 
Figure 4. Reduced NF-κB phosphorylation in PML−/− cells. WT and PML−/− MEFs were stimulated with 
(A) TNFα (10 ng/ml) or (B) IL1β (10 ng/ml) for the indicated time (minutes) and analysed by immuno-blotting 
with the indicated antibodies.
Figure 5. PML-RARα supresses NF-κB activity. WT MEFs were transfected with empty vector (control) or 
PML-RARα plasmid and were (A) treated with TNFα (10 ng/ml) for the indicated time prior to QPCR analysis 
for IL-6, ICAM1, CXCL2 and WNT11; (B) treated with TNFα (10 ng/ml) for 10 minutes prior to analysis by 
immunoblotting with the indicated antibodies.
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Figure 6. As2O3 increases TNFα induced gene expression and NF-κB phosphorylation. (A) NB4 cells 
treated with As2O3 prior to QPR analysis. (B) NB4 cells pre-treated with As2O3 (0.5 μ M) were stimulated with 
TNFα before QPCR analysis or (C) immunoblotting with the indicated antibodies.
Factor JASPAR ID z-score Fisher score
NF-κB binding sites enriched in genes upregulated by ATRA treatment of NB4 cells
NFKB MA0105.1 65.870 25.600
NF-KappaB MA0061.1 54.991 11.949
REL MA0101.1 36.077 7.155
RELA MA0107.1 35.260 8.094
NF-κ B binding sites enriched in genes bound by PML-RARα .
NF-KappaB MA0061.1 24.512 38.293
NFKB1 MA0105.1 22.585 32.796
REL MA0101.1 20.515 32.875
RELA MA0107.1 17.850 24.352
Table 1.  Enrichment of NF-κB binding sites in genes repressed by PML-RARα identified by Martens et 
al.13. JASPR ID refers to the matrix model in the JASPAR CORE database. Sites with a z-score > 10 or a Fisher 
score of > 7 are considered significantly enriched26.
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assays were performed as previously described24. The detection of over-represented conserved transcription fac-
tor binding sites was performed using oPOSSUM26. The data set used for the identification of genes repressed 
by PML-RARα expression was from the study of Martens et al.13. Gene ontology analysis was performed using 
DAVID27.
Immunoblotting, immunoprecipitations and antibodies. Whole-cell proteins were extracted using 
lysis buffer (50 mM Tris·HCl, pH 7.4, 1% Nonidet P-40, 0.25% SDS, 150 mM NaCl, 1 mM EDTA, with protease 
and phosphatase inhibitors). Anti-p65 (sc-372), anti-PML H-238 (sc-5621), anti-HDAC1 (sc-7872) purchased 
from Santa Cruz; anti-p65 phospho-S468 (3039S), anti-p65 phospho-S536 (3031S), anti-phospho-Iκ Bα (9246) 
and anti-Iκ Bα (4812), were from Cell Signalling Technology. Other antibodies used were anti-β -actin (Sigma), 
anti-hemagglutinin (HA) (Roche), anti-FLAG (Sigma), and anti-PML (mouse specific) (Millipore, 05-718).
Immunofluorescence and confocal microscopy. Cells were fixed in 4% para-formaldehyde and perme-
abilised in 0.1% Triton X-100 prior to blocking in 1% BSA. Cells were incubated with primary antibodies followed 
by Alexa Fluor 488 and 594 conjugated secondary antibody (Invitrogen). Images were acquired on a Zeiss LSM 
510 META laser scanning confocal microscope using a PlanApo 63×, 1.4 NA oil-immersion objective and a 
488 nm argon and 543 nm HeNe laser lines. Images were processed in Zeiss Zen 2011 software.
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were prepared using a Nuclear Extract 
kit (Active Motif). Reactions were prepared using 5 μ g of nuclear extract with fluorescently labelled oligonucle-
otides (5′ -AGT TGA GGG GAC TTT CCC AGG C-3′ ) (Eurofins MWG) in a 25 μ l reaction volume containing 
10 mM HEPES-KOH (pH7.9), 50 mM KCL, 2.5 mM MgCl2, 1 mM DTT, 10% glycerol, 1 μ g DNase free bovine 
serum albumin and 2.5 μ g poly[d(I-C)]. For super-shift assays the reactions were incubated with 1 μ g of anti-p65 
(sc-372) or anti-PML antibody on ice for 20 minutes before addition of the labelled oligonucleotide probe. This 
anti-p65 antibody inhibits p65 binding to the probe leading to a reduced EMSA band intensity corresponding to 
p65 DNA binding activity. Reactions were resolved on a 4% non-denaturing polyacrylamide gel.
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